Alexander disease (ALXDRD) is a rare neurodegenerative disorder of astrocytes resulting from pathogenic variants in the GFAP gene. The genotype-phenotype correlation remains elusive due to the variable expressivity of clinical manifestations. In an attempt to clarify the effects of GFAP variants in ALXDRD, numerous studies were collected and analyzed. In particular, we systematically searched for GFAP variants associated with ALXDRD and collected information on the location within the gene and protein, prediction of deleteriousness/pathogenicity, occurrence, sex and country of origin of patients, DNA source, genetic testing, and clinical signs. To identify possible associations, statistical analyses and meta-analyses were applied, thus revealing a higher than expected percentage of adult patients with ALXDRD. Furthermore, substitution of Arginine, the most frequently altered residue among the 550 predominantly missense causative GFAP variants collected, were mostly de novo and more prevalent in early-onset forms of ALXDRD. The effect of defective splicing in modifying the impact of GFAP variants on the age of onset of ALXDRD was also postulated after evaluating the distribution of the corresponding deleterious predictive values. In conclusion, not only previously unrecognized genotype-phenotype correlations were revealed in ALXDRD, but also subtle mechanisms could explain the variable manifestations of the ALXDRD clinical phenotype.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487261PMC
http://dx.doi.org/10.1038/s41598-024-75383-4DOI Listing

Publication Analysis

Top Keywords

gfap variants
16
gfap gene
8
alexander disease
8
alxdrd
8
gfap
6
variants
6
systematic review
4
review meta-analysis
4
meta-analysis gfap
4
gene variants
4

Similar Publications

Introduction: The differentiation between Alzheimer's disease (AD) and behavioral-variant frontotemporal dementia (bvFTD) can be complicated in the initial phase by shared symptoms and pathophysiological traits. Nevertheless, advancements in understanding AD's diverse pathobiology suggest the potential for establishing blood-based methods for differential diagnosis.

Methods: We devised a novel assay combining immunoprecipitation and mass spectrometry (IP-MS) to quantify Amyloid-beta (Aβ) peptides in plasma.

View Article and Find Full Text PDF

Background: Alexander disease is an autosomal dominant leukodystrophy caused by heterozygous pathogenic variants in the glial fibrillar acidic protein (GFAP) gene. Although increasingly recognised, there is evidence that Alexander disease, particularly later-onset disease, is significantly underdiagnosed and its true prevalence is unknown (the only population-based prevalence was estimated at one in 2.7 million).

View Article and Find Full Text PDF

Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders.

J Neurol Sci

December 2024

Neuropsychiatry, Royal Melbourne Hospital, 300 Grattan, St Parkville, VIC 3052, Australia; Department of Psychiatry, University of Melbourne, Grattan St Parkville, 3052 Melbourne, VIC, Australia.

Objective: Timely, accurate distinction between behavioural variant frontotemporal dementia (bvFTD) and primary psychiatric disorders (PPD) is a clinical challenge. Blood biomarkers such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) have shown promise. Prior work has shown NfL helps distinguish FTD from PPD.

View Article and Find Full Text PDF

The genetic architecture of white matter lesions (WMLs) in Asian populations has not been well-characterized. Here, we performed a genome-wide association study (GWAS) to identify loci associated with the WML volume. Brain MRI and DNA samples were collected from 9479 participants in the Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD).

View Article and Find Full Text PDF
Article Synopsis
  • Inherited motor neuron diseases (MND) like hereditary spastic paraplegias (HSP) involve the death or dysfunction of nerve cells that control muscle activity, but genetic variants may also affect other supportive cells.
  • Researchers used a rat model with a specific TFG mutation that mimics human HSP symptoms, such as motor deficits and spasticity, to investigate the source of axonopathy in the corticospinal tract.
  • Results showed that introducing the normal TFG gene into specific neurons significantly improved motor function, while targeting supportive glial cells did not yield similar benefits, highlighting the importance of neuron-focused therapies for TFG-related HSP.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!